Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry

E-ISSN： 1875-6638|11|4|317-328

ISSN： 1573-4064

Source： Medicinal Chemistry, Vol.11, Iss.4, 2015-06, pp. : 317-328

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

By Scheen André J

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 5, 2014-05 ,pp. : 647-663

Informa Healthcare

Access to resources Recommend Favorite

SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?

By Tönjes Anke Kovacs Peter

Pharmacogenomics, Vol. 14, Iss. 7, 2013-05 ,pp. : 825-833

Future Medicine

Access to resources Recommend Favorite

Discovery of 6-Deoxydapagliflozin as a Highly Potent Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Medicinal Chemistry, Vol. 10, Iss. 3, 2014-05 ,pp. : 304-317

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

By Drucker DJ

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 87-100

Informa Healthcare

Access to resources Recommend Favorite

Glucose-6-phosphatase inhibitors for the treatment of Type 2 diabetes

By Westergaard Niels Madsen Peter

Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 9, 2001-09 ,pp. : 1429-1441

Informa Healthcare

Access to resources Recommend Favorite